Bristol-Myers Squibb Company (FRA:BRM)
Germany · Delayed Price · Currency is EUR | Market Cap | 97.76B |
| Revenue (ttm) | 40.94B |
| Net Income (ttm) | 5.15B |
| Shares Out | n/a |
| EPS (ttm) | 2.53 |
| PE Ratio | 18.99 |
| Forward PE | 9.01 |
| Dividend | 2.15 (4.46%) |
| Ex-Dividend Date | Jan 2, 2026 |
| Volume | 310 |
| Average Volume | 577 |
| Open | 47.85 |
| Previous Close | 48.38 |
| Day's Range | 47.85 - 48.24 |
| 52-Week Range | 36.65 - 58.50 |
| Beta | n/a |
| RSI | 67.62 |
| Earnings Date | Feb 5, 2026 |
About FRA:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
Bristol-Myers Squibb (BMY) Upgraded to Buy with Raised Price Target | BMY Stock News
Bristol-Myers Squibb (BMY) Upgraded to Buy with Raised Price Target | BMY Stock News
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
Deep-pocketed investors have adopted a bullish approach towards Bristol-Myers Squibb (NYSE: BMY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzing...
Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference
Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 44th Annual Healthcare Conference on Monday, January 12, 2026. The company’s presentation and participat...
Looking Into Bristol-Myers Squibb Co's Recent Short Interest
Bristol-Myers Squibb Co's (NYSE: BMY) short interest as a percent of float has risen 4.19% since its last report. According to exchange reported data, there are now 35.43 million shares sold short , ...
Ex-Dividend Reminder: Encompass Health, Bristol Myers Squibb and Federal Realty Investment Trust
Looking at the universe of stocks we cover at Dividend Channel, on 1/2/26, Encompass Health Corp (Symbol: EHC), Bristol Myers Squibb Co. (Symbol: BMY), and Federal Realty Investment Trust (Symbol: FRT...
Can BMY's Growth Portfolio Drive Top-Line Expansion in 2026?
Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.
Is Bristol Myers Squibb a Buy, Sell, or Hold in 2026?
The stock has been on the rebound for several months, but can it keep the momentum going?
Biotech Stocks Facing FDA Decision In January 2026
(RTTNews) - The regulatory landscape saw several historic firsts in terms of FDA approval in December. Among them are the approval of Bristol Myers Squibb's Breyanzi - the first CAR T-cell therapy for...
Interesting BMY Put And Call Options For December 2028
Investors in Bristol Myers Squibb Co. (Symbol: BMY) saw new options begin trading today, for the December 2028 expiration. One of the key inputs that goes into the price an option buyer is willing to ...
Bristol-Myers Squibb: Contrarian Buy For Dividend Hunters, Despite Mounting Growth Headwinds
Bristol Myers Squibb: A Pharma Giant Trading Like Growth Is Over - It's Not
Bristol Myers Squibb (BMY) is undervalued and poised for growth, with strong dividends and robust financials. Read here for more analysis.
Bristol-Myers Squibb: Pharma Giant Still Undervalued And Printing Cash Despite Patent Cliff
Bristol-Myers Squibb Surges Into Year-End: Why BMY Still Looks Undervalued
FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug
Reviva Pharmaceuticals Holdings Inc . (NASDAQ: RVPH) on Tuesday announced a regulatory update following a pre-New Drug Application (pre-NDA) meeting with the U.S. Food and Drug Administration (FDA). ...
Bristol-Myers Squibb: Still Undervalued And Generating 4.65% Dividend Yield
Bristol-Myers Squibb: Recent Gains Impress, But Tricky Tests Lie Ahead
Cytokinetics Wins FDA Nod For Heart Drug Myqorzo
On Friday, the U.S. Food and Drug Administration (FDA) approved Cytokinetics Incorporated’s (NASDAQ: CYTK) Myqorzo ( aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to impro...
Bristol Myers Squibb (BMY) to Provide Eliquis Free to Medicaid
Bristol Myers Squibb (BMY) to Provide Eliquis Free to Medicaid
Bristol-Myers blood thinner Eliquis offered free to Medicaid as part of U.S. pricing deal
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal
President Donald Trump and nine major pharmaceutical companies announced agreements to lower the cost of medications for cash payers and the government’s Medicaid program on Friday, bringing U.S. cost...
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
Bristol Myers Squibb (BMY) closed at $54.19 in the latest trading session, marking a +1.61% move from the prior day.
Bristol Myers Squibb (BMY) Joins New Deal to Lower Drug Prices in U.S.
Bristol Myers Squibb (BMY) Joins New Deal to Lower Drug Prices in U.S.
Bristol Myers (BMY) Enhances Access to Eliquis with Landmark Agreement
Bristol Myers (BMY) Enhances Access to Eliquis with Landmark Agreement
Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts
As big pharmaceutical companies are set to finalize a deal with the U.S. government to bring down prices for some prescription drugs, another old question is coming into focus for investors: how much ...
Trump strikes deal with US drugmakers to cut Medicaid medicine costs
Officials pledge ‘massive savings’ as companies agree to offer drugs at prices equal to those in other wealthy nations Donald Trump and nine major pharmaceutical companies on Friday announced deals th...